Aspire BioPharma, Inc. (ASBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has a cash flow conversion efficiency ratio of 0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($-11.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aspire BioPharma, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Aspire BioPharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Aspire BioPharma, Inc. (ASBP) financial obligations for a breakdown of total debt and financial obligations.
Aspire BioPharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aspire BioPharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
General Shopping e Outlets do Brasil S.A.
SA:GSHP3
|
0.029x |
|
The Alumasc Group plc
LSE:ALU
|
0.068x |
|
Queste Communications Ltd
AU:QUE
|
-0.039x |
|
X3 Holdings Co Ltd
NASDAQ:XTKG
|
-0.040x |
|
Story-I Ltd
AU:SRY
|
3.211x |
|
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
|
0.002x |
|
LUNGLIFE AI INC. DL-0001
F:9H4
|
N/A |
|
Marksmen Energy Inc
V:MAH
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Aspire BioPharma, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see ASBP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.54 Million | $-265.19K | 0.172x | +616.19% |
| 2023-12-31 | $19.58 Million | $-653.11K | -0.033x | -584.45% |
| 2022-12-31 | $289.07 Million | $-1.41 Million | -0.005x | -100.89% |
| 2021-12-31 | $-475.00 | $-260.00 | 0.547x | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for subl… Read more